TG Therapeutics, Inc.
TGTXHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Part of the healthcare sector, TG Therapeutics, Inc. (TGTX) is listed under Biotechnology. With a market capitalization of $5.94B, it sits in mid-cap territory. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Market Cap
$5.94B
Beta
1.68
P/E (TTM)
13.57
P/E (Fwd)
13.39
EPS (TTM)
$2.86
EPS (Fwd)
$2.90
ROE
112.6%
ROA
8.6%
Cash
$514.4M
Total Debt
$753.6M
Free CF
-$30.2M
52W Change
10.6%
Annual Financials
Cash vs Debt
TG Therapeutics, Inc. carries $753.6M in total debt against $514.4M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$30.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 112.6%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.8M (2022) to $616.3M (2025), reflecting a 22029% increase over the period.
A beta of 1.68 means TGTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TG Therapeutics, Inc. and its sector.